• Explore /
  • Poster
  • / Camrelizumab in combination with apatinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: A prospective, single-arm, phase 2 study.

Camrelizumab in combination with apatinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: A prospective, single-arm, phase 2 study.

Abstract Poster

Authors

null

Yunlong Cui

Tianjin Medical University Cancer Hospital & Institute, Tianjin, China

Yunlong Cui , Xu Bao , Ge Yu , Huikai Li , Feng Fang , Qiang Li , Wei Zhang , Qiang Wu , Lu Chen , Chen Liu , Tianqiang Song

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer - Local-Regional Disease

Clinical Trial Registration Number

NCT04701060

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4120)

DOI

10.1200/JCO.2023.41.16_suppl.4120

Abstract #

4120

Poster Bd #

441

Abstract Disclosures

Similar Posters

First Author: Yang-Kui Gu

First Author: Hong Zhao

First Author: Zheng Wu

First Author: Yongxiang Xia